The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs

Logan, Richard M.; Stringer, Andrea M.; Bowen, Joanne M.; Yeoh, Ann S. J.; Gibson, Rachel J.; Sonis, Stephen T.; Keefe, Dorothy

doi:10.1016/j.ctrv.2007.03.001

Cited by 236 publications

(217 citation statements)

References 114 publications

Supporting

Mentioning

205

Contrasting

Unclassified

Order By: Relevance

“…An alternative hypothesis is that fever may be a manifestation of the inflammatory process that is induced by conditioning chemotherapy 2,[15][16][17] and driven by acute phase cytokines such as tumour necrosis factor a (TNF-a) and interleukin 6 (IL-6). 17,18 Mucositis itself is also a potential source of local and systemic cytokines. These cytokines can induce sepsis-like signs and symptoms when administered exogenously to humans.…”

Section: Discussionmentioning

confidence: 99%

The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT

McCann

Schwenkglenks

Bacon

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

The Prospective Oral Mucositis Audit was an observational study in 197 patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) undergoing, respectively, high-dose melphalan or BEAM chemotherapy and autologous SCT at 25 European centres. We evaluated the relationship between severe oral mucositis (SOM; WHO Oral Toxicity Scale grade 3-4) and local and systemic clinical sequelae and medical resource use. SOM occurred in 44% of patients. The duration of SOM (mean 5.3 days) correlated with time to neutrophil engraftment. The following parameters increased gradiently with maximum grade of oral mucositis: duration of pain score X4, opioid use, dysphagia score X4, total parenteral nutrition (TPN) use, incidence and/or duration of fever and infection, and duration of antibiotic use. SOM increased the duration of TPN use by 2.7 days (Po0.001), opioids by 4.6 days (Po0.001), and antibiotics by 2.4 days (P ¼ 0.045). SOM prolonged hospital stay by 2.3 days (P ¼ 0.013) in MM patients, but not in NHL patients (who tended to have a longer hospital stay).In conclusion, this analysis of prospectively collected observational data provides important insight into the scope and impact of SOM in the European transplant setting.

show abstract

Section: Discussionmentioning

confidence: 99%

The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT

McCann

Schwenkglenks

Bacon

et al. 2008

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Akbulut et al demonstrated the cytoprotective effects of amifostine, ascorbic acid and N-acetylcysteine against Mtx-induced hepatotoxicity in rats (4). In addition, it has been reported that proinfl ammatory cytokines are involved in the pathogenesis of Mtx-induced nephrotoxicity and pneumonitis, suggesting that infl ammation may also have a possible role in Mtx-induced hepatotoxicity (11)(12)(13)(14)(15)(16).…”

Section: Introductionmentioning

confidence: 99%

The effects of lycopene on methotrexate-induced liver injury in rats

Yucel¹,

Oğuz²,

Koçarslan³

et al. 2017

BLL

View full text Add to dashboard Cite

BACKGROUND: The aim of this study was to investigate the effects of lycopene (Lyc) on methotrexate (Mtx) induced liver toxicity in rats. METHODS: Twenty-eight male Sprague-Dawley rats were divided into four equal groups: control, Lyc, Mtx and Mtx-L: Control group: Rats were given only the vehicle. Lyc group: Rats were given Lyc (10 mg/kg) with corn oil by oral gavage for ten days. Mtx group: Rats were injected intraperitoneally with a single dose of 20 mg/kg of Mtx and given corn oil by oral gavage. Mtx-L group: Rats were post-treated with Lyc (10 mg/kg) for ten days after a single dose of Mtx (20 mg/kg). RESULTS: Mtx administration increased histopathological damage, TNF-α, IL-1β, TOS, TAS and OSI levels in tissues; AST, ALT levels in the blood. Sinusoidal dilatation, infl ammatory cell infi ltration and congestion were signifi cantly improved in the Mtx-L aon histopathologic examination of the rats. In Mtx-L group that were treated at the Lyc, TNF-α and IL-1β levels of liver tissue were decreased signifi cantly compared to Mtx group whereas the decrease in OSI was not signifi cant. Lyc treatment improved the AST and ALT values in Mtx-L group. But only AST improvement was signifi cant. CONCLUSIONS: The results of this study revealed that Lyc might be useful in protecting the liver from injury due to Mtx in rats by reducing the increased proinfl ammatory cytokine levels (Tab. 4, Fig. 1, Ref. 44). Text in PDF www.elis.sk.

show abstract

“…Cytokines are proteins or glycoproteins that modulate inflammatory and immune responses. There is evidence to suggest that pro-inflammatory cytokines including interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-alpha play an important role in the pathogenesis of mucositis [1].…”

Section: Introductionmentioning

confidence: 99%

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

Raber-Durlacher

Bültzingslöwen²,

Logan

et al. 2012

Support Care Cancer

Self Cite

112

View full text Add to dashboard Cite

Purpose The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the prevention or treatment of oral mucositis induced by cancer chemotherapy or radiotherapy. Care Cancer (2013) 21:343-355 DOI 10.1007/s00520-012-1594 following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible. Results Sixty-four clinical studies across 11 interventions were evaluated. A recommendation was made for the use of recombinant human KGF-1 (palifermin) at a dose of 60 μg/kg per day for 3 days prior to conditioning treatment and for 3 days post-transplant for prevention of oral mucositis in patients receiving high-dose chemotherapy and total body irradiation followed by autologous stem cell transplantation for hematological malignancies. A suggestion was made against using granulocyte macrophage colony-stimulating factor mouthwash for the prevention of oral mucositis in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation. No guideline was possible for any other cytokine or growth factor agents due to inconclusive evidence. Conclusions Of the cytokine and growth factor agents studied for oral mucositis, the evidence only supports use of palifermin in the specific population listed above. Additional welldesigned research is needed on other cytokine and growth factor interventions and in other cancer treatment settings. Methods

show abstract

The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: Pathobiology, animal models and cytotoxic drugs

Cited by 236 publications

References 114 publications

The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT

The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT

The effects of lycopene on methotrexate-induced liver injury in rats

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

Contact Info

Product

Resources

About